Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

Kowalski, Jörg

doi:10.1016/s1536-1632(03)00038-6

Cited by 284 publications

(135 citation statements)

References 8 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…2,3 Recently 68 Ga-DOTATOC has been shown to be more accurate than conventional imaging with 111 Indiumpentetreotide. [5][6][7] Our results are the first to report on the use of PET-CT with the related 68 Ga-DOTA peptide DOTATATE. By using a receptor-targeted approach with 68 Ga-DOTATATE we have shown an improvement in diagnostic performance of PET-CT imaging of NET tumors relative to 18 F-FDG.…”

Section: Discussionmentioning

confidence: 76%

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Kayani¹,

Bomanji²,

Groves³

et al. 2008

Cancer

433

349

View full text Add to dashboard Cite

BACKGROUND. The aim was to assess the relevant distribution of the novel PET tracer 68Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission tomography / computed tomography (PET/CT) and compare its performance with that of 18F‐FDG PET/CT. METHODS. The imaging findings with 68Ga‐DOTATATE and 18F‐FDG on 38 consecutive patients with a diagnosis of primary or recurrent NET were compared and correlated with tumor grade on histology based on ki67 and mitotic index. RESULTS. The sensitivity of 68Ga‐DOTATATE PET/CT was 82% (31 of 38) and that of 18F‐FDG PET/CT was 66% (25 of 38). The sensitivity of combined 68Ga‐DOTATATE and 18F‐FDG PET/CT was 92% (35 of 38). There was greater uptake of 68Ga‐DOTATATE than 18F‐FDG in low‐grade NET (median SUV 29 vs 2.9, P < .001). In high‐grade NET there was higher uptake of 18F‐FDG over 68Ga‐DOTATATE (median SUV 11.7 vs 4.4, P = .03). There was a significant correlation with predominant tumor uptake of 68Ga‐DOTATATE or 18F‐FDG and tumor grade on histology (P < .0001). CONCLUSIONS. 68Ga‐DOTATATE PET/CT is a useful novel imaging modality for NETs and is superior to 18F‐FDG for imaging well‐differentiated NET. Functional imaging with both 68Ga‐DOTATATE and 18F‐FDG has potential for a more comprehensive tumor assessment in intermediate‐ and high‐grade tumors. Cancer 2008. ©2008 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 76%

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Kayani¹,

Bomanji²,

Groves³

et al. 2008

Cancer

433

349

View full text Add to dashboard Cite

show abstract

“…As compared to In-111 pentetreotide imaging, PET scan with Ga-68 DOTA peptides detects more lesions, shows higher uptake in the lesions and provides shorter time of acquisition and lower radiation exposure [24,26].…”

Section: Radionuclide Sstr Imagingmentioning

confidence: 99%

Significance of splenic uptake on somatostatin receptor imaging studies

Sarıkaya¹,

Sarıkaya²,

Alnafisi³

et al. 2018

Nucl. Med. Rev.

View full text Add to dashboard Cite

Spleen shows a high physiological uptake on radionuclide somatostatin receptor (SSTR) imaging studies. Autoradiography and immunohistochemistry studies showed that SSTRs are mainly located in the red pulp of the spleen. In this review article we will summarize the significance of splenic uptake in SSTR imaging studies and will also present high resolution splenic images of Ga-68 DOTANOC PET in which splenic distribution of the radiotracer appears to be correlating with the distribution of red pulp.

show abstract

“…The most widely studied 68 Ga-DOTA-octreotide analogs for PET imaging are 68 Ga-DOTATATE, 68 Ga-DOTATOC, and 68 Ga-DOTANOC. All of these radiopharmaceuticals have higher affinity than 111 In-octreotide for the somatostatin receptor subtype 2, the primary target in NETs, and are more sensitive than 111 In-octreotide in the detection of NET lesions (6)(7)(8).…”

mentioning

confidence: 99%

Localization of Unknown Primary Site with ⁶⁸Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

et al. 2017

View full text Add to dashboard Cite

Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases. Methods: Forty patients with metastatic NET and unknown primary site underwent 68 Ga-DOTATOC PET/ CT in a single-site prospective study. The 68 Ga-DOTATOC PET/ CT was considered true-positive if the positive primary site was confirmed by histology or follow-up imaging. The scan was considered false-positive if no primary lesion was found corresponding to the 68 Ga-DOTATOC-positive site. All negative scans for primary tumor were considered false-negative. A scan was classified unconfirmed if 68 Ga-DOTATOC PET/CT suggested a primary, however, no histology was obtained and imaging follow-up was not confirmatory. Results: The true-positive, false-positive, falsenegative, and unconfirmed rates for unknown primary tumor were 38%, 7%, 50%, and 5%, respectively. Conclusion: 68 Ga-DOTATOC PET/CT is an effective modality in the localization of unknown primary in patients with metastatic NET.

show abstract

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

Cited by 284 publications

References 8 publications

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Significance of splenic uptake on somatostatin receptor imaging studies

Localization of Unknown Primary Site with ⁶⁸Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

Contact Info

Product

Resources

About

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

Cited by 284 publications

References 8 publications

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG

Significance of splenic uptake on somatostatin receptor imaging studies

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

Contact Info

Product

Resources

About

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Localization of Unknown Primary Site with ⁶⁸Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor